ALMS Alumis Inc.

$ALMS this can be acquired at 15-17. The only psoriasis oral drug not with big pharma. NDA any day now.

$ALMS constant accumulation over the last few days off the lows, shorts can sit and watch their gains evaporate. There’s a reason the big boys sold over 20k+ Jan 2027 $7 puts (2M +share equivalent). They made a ton collecting that premium and don’t mind getting exercised bc they’re accumulating everything they can at these levels. All the data about Envu is pointing to a big home run for ALMS. They just need to monetize all that potential ASAP.

$ALMS my average price is 7.79 dollars, I am fully all in, probably I am taking a huge risk but I believe I can easy double my money

$ALMS they need to file that fda application asap and seek a partner for commercialization. They’ve got a good product going via their psoriasis drug.. let’s hope management doesn’t botch this opportunity.

$ALMS has new Phase 3 data showing rapid, durable scalp clearance and itch relief for psoriasis, keeping NDA filing on track for Q4 2026.

$ALMS the short thesis on this is now dead after the bullish confirmation from the company on phase 3 results. Tax loss sellers from the largest volume first week after the big drop are now eligible to buy back after the wash sale window, with more and more eligible every day. The 6.6x bottoming range held and bounced, the big boys have a green light to accumulate now.

$ALMS cannot believe Otezla generates roughly $2.1 billion to $2.3 billion in annual revenue for Amgen. According to Amgen’s official financial reports, its recent full-year global sales figures are: • 2025: $2.27 billion (a 7% increase year-over-year) • 2024: $2.10 billion. why ALMS is not worth anything? weird

$ALMS your disrespect of its soft, red flaccidity has awakened its tumescent green cucumber.

$ALMS Relax ,you shorts will come back from the t1👀 $100$ open . It would be tough to wake up to ⏰️ though ...GL 😕 😒

$ALMS Initial entry at $3, followed by a second at $2, but proceed with caution, as the FDA could reject Alumis's therapy, which would cause the company to fail.